本研究的目的是根据美国环保局指南（美国环保局2005）进行定量风险评估，其中考虑了TBA诱发大鼠肾肿瘤和小鼠甲状腺肿瘤的作用方式数据。当来自动物研究的数据，如TBA生物测定，被外推到人类身上，以提供终生癌症风险的估计，然后，在估算人体等效剂量时，以及在从动物生物测定中通常使用的高剂量推断到人类可能接触的低剂量时，考虑动物物种和人类之间药代动力学（代谢）和药效学（敏感性和作用模式）的潜在差异。回顾了TBA的药代动力学、毒性和作用方式数据，并选择了用于定量剂量反应建模的数据。

The purpose of this investigation was to conduct a quantitative risk assessment according to USEPA guidelines (USEPA 2005) in which data on the mode of action by which TBA induced renal tumors in rats and thyroid tumors in mice was considered. When data from animal studies, such as the TBA bioassays, are extrapolated to humans to provide estimates of lifetime cancer risks, then potential differences in pharmacokinetics (metabolism) and pharmacodynamics (sensitivity and mode of action) between the animal species and humans is considered in the estimation of human equivalent doses and in extrapolation from high doses typically used in the animal bioassays to low doses to which humans may be potentially exposed. Pharmacokinetic, toxicity, and mode of action data for TBA were reviewed and data selected for quantitative dose-response modeling.